Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor-positive, HER2-negative Breast Cancer. JCOG2313, AURA Trial.

NCT07190443 is registered in ClinicalTrials.gov with Japanese Foundation for Cancer Research as lead sponsor.

NCT NCT07190443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07190443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor-positive, HER2-negative Breast Cancer. JCOG2313, AURA Trial.
Lead sponsor
Japanese Foundation for Cancer Research
Phase
Phase 3
Overall status
Recruiting
Start date
February 7, 2025
Completion date
February 6, 2035
Enrollment
290 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abemaciclib, breast cancer, endocrine therapy, locoregional recurrence